Search

Your search keyword '"Drouet E"' showing total 305 results

Search Constraints

Start Over You searched for: Author "Drouet E" Remove constraint Author: "Drouet E"
305 results on '"Drouet E"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. POS0046 PRELIMINARY RESULTS OF AN OPEN-LABEL, MULTICENTRE, PHASE 1/2 STUDY TO ASSESS SAFETY, EFFICACY AND CELLULAR KINETICS OF YTB323 (RAPCABTAGENE AUTOLEUCEL), A RAPIDLY MANUFACTURED CAR T-CELL THERAPY TARGETING CD19 ON B CELLS, FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

4. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

5. Impact of transfusion on platelet aggregation and biomarkers in myocardial infarction patients with anemia: an ancillary study of the randomized REALITY trial

6. Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.

9. LBA38 BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours

10. 611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors

11. BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours

14. LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors

15. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

17. OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS

18. BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors

19. LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)

20. Allogeneic stem cell transplantation for acquired pure red cell aplasia

26. Compared prognostic impact of incident atrial fibrillation versus history of atrial fibrillation in patients with AMI: the FAST-MI programme

28. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

29. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

35. P491Different prognostic impact of pre-percutaneous coronary intervention TIMI flow in ST and non-ST elevation myocardial infarction patients: results from the FAST-MI 2010 registry

36. P1246Age-, body size-, and sex-specific reference values for tricuspid valve apparatus parameters by real-time three-dimensional transthoracic echocardiographyP1247Surgical therapy in infective endocarditis: predisposing and prognostic factorsP1248Evalutation of MV annulus geometry modifications before and after mitraclip implantation with 3D transesophageal echocardiographyP1249Prognostic echocardiographic parameters for successful transcatheter edge-to-edge mitral valve repairP1250Influence of body surface area in diagnosis and outcome patient-prosthesis mismatch after TAVI. Is it necessary to adjust for ideal body weight?P1251Outcome of paradoxical low-flow low-gradient severe AS following TAVI: paradoxical VS parallel to outcome of high gradient ASP1252Prognostic role of cardiac calcifications in subjects without overt significant heart disease and previous cardiovascular events: is there an additive value over cardiovascular risk factors scores?P1253Aging degeneration of mitral valve without leaflet prolapse or tethering as a cause of severe mitral regurgitationP1254Cardiovascular risk assessment should be performed in patients with incidental aortic sclerosisP1255Cardiac valve calcification score: simple 2D echocardiographic tool for cardiovascular risk stratification in patients with chronic renal failureP1256Diastolic mitral regurgitation following transcatheter aortic valve replacement: prevalence, predictors and impact on outcomesP1257Timing of myocardial shortening determines left ventricular regional remodelling in hearts with conduction delaysP1258Myocardial stiffness assessment using shear wave imaging in healthy children and hypertrophic cardiomyopathyP1259Assessment of right ventricular response to exercise using vector velocity imaging in hypertrophic cardiomyopathyP1260Diagnostic value of cardiac biomarkers (high sensitive troponin T and N-terminal pro-brain natriuretic peptide) in patients with infiltrative cardiomyopathiesP1261Right ventricular global longitudinal strain differentiates between adolescent patients with definite, borderline and possible ARVC and controlsP1262 echogrqphic predictif factors of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasiaP1263Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fractionP1264Chronotropic response in mitochondrial (ANT1) cardiomyopathyP1265 The effect of cardiovascular risk factors and cancer type in anthracycline's cardiotoxicityP1266Revisiting the echocardiographic features of acute myocarditisP1267Altered circulation in fetuses of diabetic mothers: a fetal computational model analysisP1268Increased epicardial adipose tissue is related to stress-induced cardiomyopathyP1269Contrast enhanced ultrasound of kidney perfusion in patients with renal artery stenosis: diagnostic and prognostic applications.

43. Chronic restraint stress induces severe disruption of the T-cell specific response to tetanus toxin vaccine

46. Poster session Thursday 6 December - AM: Other myocardial diseases

Catalog

Books, media, physical & digital resources